Use of MVA to treat prostate cancer
US8377688B2 · kind B2 · utility
20Cited by
7References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 30, 2010 |
| Grant date | Feb 19, 2013 |
| Priority date | — |
| Expiry date | Dec 14, 2030 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2830/60
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to compositions, kits, and methods for cancer prophylaxis and therapy using recombinant MVA viruses encoding tumor-associated antigens, such as PSA and PAP. The recombinant MVA viruses can induce B-and T-cell responses. The recombinant MVA viruses can be administered prior to, at the same time as, or after a taxane.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.